Skip to content

Leg Heating in Pregnant Women With Obesity

Vascular and Neural Mechanisms of Chronic Leg Heating in Pregnant Women With Obesity

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06932250
Enrollment
118
Registered
2025-04-17
Start date
2025-08-01
Completion date
2030-04-30
Last updated
2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-risk Pregnancy

Keywords

Pregnancy, Obesity, Heat therapy, Vascular function, Sympathetic neural control, Blood pressure

Brief summary

Obesity is a major risk factor for hypertensive disorders of pregnancy (HDP). The underlying mechanisms are largely unclear, but maternal vascular endothelial dysfunction is likely involved. Endothelial dysfunction in HDP could be attributed to 1) alterations in the L-arginine/nitric oxide (NO) pathway, and 2) an increase in endothelin-1 (ET-1). Additionally, augmented sympathetic vasoconstriction may also contribute to HDP. Chronic (repeated) whole-body heat exposure has been shown to increase NO bioavailability, decrease ET-1, and cause functional and structural adaptations in the vasculature. All these can improve vascular function, attenuate sympathetic (re)activity, lower blood pressure (BP), and reduce cardiovascular risk in non-pregnant individuals. Whether this is also true after regional (leg) heating in high-risk pregnant women is unknown. The investigators' central hypothesis is that chronic leg heating will be effective in improving vascular endothelial function and attenuating sympathetic vasoconstriction, leading to a reduction of the risk for HDP in pregnant women with obesity. The overarching goal of this proposal is to determine the vascular and neural effects of chronic leg heating in obese pregnancy. The study team plans to enroll pregnant women with obesity between 12-14 weeks of gestation and randomly assign them to either an intervention group or a control group (1:1 ratio). Participants in the intervention group will perform 16 weeks of home-based leg heating using a portable sauna blanket up to the hip (temperature of the blanket will be set at 65°C, 4 times/week, 45 min/session), whereas women in the control group will set the temperature of the blanket at 35°C at the same frequency and duration. Participants will be evaluated at baseline and then at 28-30 weeks of gestation. Aim 1 will determine the effects of chronic leg heating on maternal vascular function and surrogate markers of HDP. Aim 2 will determine the effects of chronic leg heating on sympathetic vasoconstriction and BP. Findings from this project will provide insight on the extent and potential mechanisms of how chronic leg heating works for improving vascular endothelial function and sympathetic vasoconstriction in pregnant women with obesity. Results obtained will set a foundation for future large multicenter clinical trials to determine the efficacy and generalizability of home-based leg heat therapy as a safe, ease-of-use, cost-effective, and non-drug approach for reducing the risk of HDP.

Detailed description

Obesity is a major risk factor for hypertensive disorders of pregnancy (HDP). The underlying mechanisms are unclear, but maternal vascular endothelial dysfunction is likely involved. Endothelial dysfunction in HDP could be attributed in part to: 1) alterations in the L-arginine/nitric oxide (NO) pathway, and 2) an increase in endothelin-1 (ET-1). Conversely, augmented sympathetic vasoconstriction may also contribute to the development of HDP in women with obesity. Exercise training increases NO production, decreases ET-1, improves vascular function, attenuates sympathetic (re)activity, and reduces the risk for HDP. However, pregnant women, especially those with obesity, have poor adherence to exercise. Thus, there is an urgent need to develop novel, safe, convenient, low-cost, and well-tolerated strategies that have similar beneficial effects as exercise training. One such novel approach may be "heating". During passive whole-body heating, body core temperature increases and cutaneous and muscle vascular resistance decreases, leading to increases in blood flow and shear stress throughout the entire arterial tree. Chronic (i.e., repeated) exposure to these temperature-dependent responses induces an increase in NO bioavailability, a decrease in ET-1, and functional and structural adaptations in the vasculature - all these can improve vascular function, attenuate sympathetic (re)activity, lower blood pressure (BP), and reduce the risk for cardiovascular morbidity and mortality. Evidence suggests that maternal body core temperature below 38.9°C is safe for the fetus. The study team proposes to use regional (e.g., leg) rather than whole-body (e.g., hot tub or sauna) heating, since leg heating does not substantially elevate body core temperature (i.e., 37.32°C at peak in pregnant women with obesity in our pilot study), is more tolerable than whole-body heating, and can be performed in-home. Importantly, the study team's preliminary work showed that chronic home-based leg heating is safe, and can improve endothelial function, attenuate sympathetic vasoconstriction, and reduce ambulatory awake BP in pregnant women with obesity. The investigators' central hypothesis is that chronic leg heating will be effective in improving vascular endothelial function and attenuating sympathetic vasoconstriction, leading to a reduction of the risk for HDP in pregnant women with obesity. Aim 1: Determine the effects of chronic leg heating on maternal vascular function and surrogate markers of HDP. Hypothesis 1: Chronic leg heating will improve vascular endothelial function due to an increase in NO bioavailability and a decrease in ET-1, which may be associated with a reduction of the risk for HDP in pregnant women with obesity. Aim 2: Determine the effects of chronic leg heating on sympathetic vasoconstriction and BP. Hypothesis 2: Chronic leg heating will attenuate sympathetic-dependent vasoconstriction due to a decrease in sympathetic (re)activity, which may be associated with a reduction of BP in pregnant women with obesity. Impact: Findings from this project will provide insight on the extent and potential mechanisms of how chronic leg heating works for improving vascular endothelial function and sympathetic vasoconstriction in pregnant women with obesity. Results obtained will set a foundation for future large multicenter clinical trials to determine the efficacy and generalizability of home-based leg heat therapy as a safe, ease-of-use, cost-effective, and non-drug approach for reducing the risk of HDP, and its most severe form, preeclampsia.

Interventions

OTHERLeg heating

Participants will perform home-based leg heating using a portable sauna blanket set at different temperature.

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Women with overweight or obesity (self-reported pre-pregnancy body mass index ≥25 kg/m2) between 10-14 weeks of gestation and aged 18-45 years old will be enrolled. * Both normotensive and hypertensive (office sitting systolic BP 140-150 mmHg and/or diastolic BP 90-100 mmHg) pregnant women will be enrolled if they are not on any antihypertensive drug treatment. * We will enroll both nulliparous and multiparous women. * There is no restriction regarding race/ethnicity and socioeconomic status. * Women with a history of HDP will be allowed to participate. * Women taking low-dose aspirin will be allowed to participate and aspirin use will be documented.

Exclusion criteria

* Current multiple pregnancies (e.g., twins, triplets, etc.). * Known major fetal chromosomal or anatomical abnormalities diagnosed during the study. * Recurrent miscarriage (three or more, to avoid antiphospholipid antibody syndrome). * Office sitting BP \<100/55 mmHg or \>150/100 mmHg (for safety reasons). * Evidence of cardiovascular, pulmonary, or neurological diseases. * Diabetes mellitus (to avoid its effects on vascular endothelial function and sympathetic vasoconstriction). * Kidney disease (serum creatinine \>0.9 mg/dL). * Clinical known deep vein thrombosis, clinical symptoms and history of deep vein thrombosis, or dermatological lesions. * History of drug or alcohol abuse within the last 2 years. * Current tobacco use. * Pregnant women who do not have air conditioning at home during summer (for safety reasons).

Design outcomes

Primary

MeasureTime frameDescription
Change in vascular endothelial functionBaseline, 16 weeks after leg heatingChange in vascular endothelial function assessed by brachial artery flow-mediated vasodilation using the Doppler ultrasound technique
Change in sympathetic neural controlBaseline, 16 weeks after leg heatingChange in sympathetic neural control assessed by muscle sympathetic nerve (re)activity using the microneurographic technique
Change in sympathetic vascular transductionBaseline, 16 weeks after leg heatingChange in sympathetic vascular transduction assessed using the microneurographic and Doppler ultrasound techniques

Secondary

MeasureTime frameDescription
Change in blood concentration of nitrateBaseline, 16 weeks after leg heatingBlood concentration of nitrate will be used to estimate nitric oxide bioavailability
Change in blood concentration of nitriteBaseline, 16 weeks after leg heatingBlood concentration of nitrite will be used to estimate nitric oxide bioavailability
Change in L-arginine levelBaseline, 16 weeks after leg heating
Change in asymmetric dimethylarginine levelBaseline, 16 weeks after leg heating
Change in 3-nitrotyrosine levelBaseline, 16 weeks after leg heating
Change in concentration of endothelin-1Baseline, 16 weeks after leg heating
Change in 24-hour ambulatory blood pressureBaseline, 16 weeks after leg heating
Change in placental growth factor levelBaseline, 16 weeks after leg heating
Change in solube fms-like tyrosine kinase-1 levelBaseline, 16 weeks after leg heating
Change in soluble endoglin levelBaseline, 16 weeks after leg heating

Countries

United States

Contacts

CONTACTQi Fu, MD, PhD
QiFu@TexasHealth.org214-345-8125
CONTACTMonique Roberts-Reeves, RN
MoniqueRoberts-Reeves@TexasHealth.org214-345-4656
PRINCIPAL_INVESTIGATORQi Fu, MD, PhD

UT Southwestern Medical Center; Institute for Exercise and Environmental Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026